Citius Pharmaceuticals is trading 5.3% up at $0.56 in after-hours trading as the stock appears to stage a modest rebound following recent declines.
- No fresh company-specific announcements or earnings releases were issued on July 14 to clearly explain the price action.
- Recent news flow has centered on pipeline milestones, including Mino-Lok Phase 3 success and LYMPHIR data.
- The upward move occurs within a generally positive market backdrop despite the lack of immediate catalysts.